Wilkinson R H
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
J Nucl Med. 1996 Apr;37(4):636-9.
A patient with postoperative Stage I ovarian carcinoma received 15 mCi of 32P-chromic phosphate suspension in normal saline intraperitoneally as part of her therapy. The following day, a portion of the infused radiopharmaceutical and normal saline had passed transdiaphragmatically into the patient's right pleural cavity. Thoracentesis removed as much fluid as possible and this fluid contained radioactive material. In the ensuing 4 yr, the patient has not manifested any detectable pleural or pulmonary abnormalities attributable to the radioactivity. Retrospective review of 100 consecutive patients receiving 32P-chromic phosphate intraperitoneal therapy resulted in 43 patients in whom the hemithoraces could be evaluated scintigraphically. Three of the 43 patients (7%) had right pleural fluid radioactivity. This is similar to the percentages reported in patients with cirrhosis with ascites in whom hepatic hydrothorax is identified.
一名术后I期卵巢癌患者接受了15毫居里的32P-磷酸铬悬浮液与生理盐水混合后经腹腔内给药，作为其治疗的一部分。第二天，一部分注入的放射性药物和生理盐水经横膈膜进入了患者的右胸腔。胸腔穿刺术尽可能多地抽出了液体，且该液体含有放射性物质。在随后的4年里，该患者未出现任何可归因于放射性的可检测到的胸膜或肺部异常。对连续100例接受32P-磷酸铬腹腔内治疗的患者进行回顾性研究，结果显示43例患者的半侧胸腔可通过闪烁扫描进行评估。这43例患者中有3例（7%）右侧胸腔积液有放射性。这与已报道的肝硬化腹水患者中发现肝性胸水的百分比相似。
